Annual Accounts Receivable
$290.40 K
-$816.90 K-73.77%
December 31, 2023
Summary
- As of February 7, 2025, SLN annual accounts receivable is $290.40 thousand, with the most recent change of -$816.90 thousand (-73.77%) on December 31, 2023.
- During the last 3 years, SLN annual accounts receivable has fallen by -$39.65 million (-99.27%).
- SLN annual accounts receivable is now -99.27% below its all-time high of $39.94 million, reached on December 31, 2020.
Performance
SLN Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$385.40 K
-$1.75 M-81.93%
September 1, 2024
Summary
- As of February 7, 2025, SLN quarterly accounts receivable is $385.40 thousand, with the most recent change of -$1.75 million (-81.93%) on September 1, 2024.
- Over the past year, SLN quarterly accounts receivable has increased by +$95.00 thousand (+32.71%).
- SLN quarterly accounts receivable is now -99.05% below its all-time high of $40.53 million, reached on June 30, 2020.
Performance
SLN Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
SLN Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -73.8% | +32.7% |
| 3 y3 years | -99.3% | -65.2% |
| 5 y5 years | +100.0% | -65.2% |
SLN Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -73.8% | at low | -97.5% | +165.4% |
| 5 y | 5-year | -99.3% | +5484.6% | -99.0% | -100.0% |
| alltime | all time | -99.3% | -100.0% | -99.0% | -100.0% |
Silence Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $385.40 K(-81.9%) |
| Jun 2024 | - | $2.13 M(-79.2%) |
| Mar 2024 | - | $10.28 M(+3438.8%) |
| Dec 2023 | $290.40 K(-73.8%) | $290.40 K(-48.5%) |
| Sep 2023 | - | $563.70 K(-96.4%) |
| Jun 2023 | - | $15.54 M(+641.3%) |
| Mar 2023 | - | $2.10 M(+89.4%) |
| Dec 2022 | $1.11 M(+147.9%) | $1.11 M(+662.6%) |
| Sep 2022 | - | $145.20 K(-95.9%) |
| Jun 2022 | - | $3.52 M(+4.1%) |
| Mar 2022 | - | $3.38 M(+656.9%) |
| Dec 2021 | $446.70 K(-98.9%) | $446.70 K(>+9900.0%) |
| Sep 2021 | - | $0.00(-100.0%) |
| Jun 2021 | - | $606.20 K(-98.5%) |
| Dec 2020 | $39.94 M(>+9900.0%) | $39.94 M(-1.5%) |
| Jun 2020 | - | $40.53 M(>+9900.0%) |
| Dec 2019 | $5200.00(>+9900.0%) | - |
| Dec 2019 | - | $5200.00(>+9900.0%) |
| Jun 2019 | - | $0.00(0.0%) |
| Dec 2018 | $0.00(0.0%) | - |
| Dec 2018 | - | $0.00(-100.0%) |
| Jun 2018 | - | $1.49 M(>+9900.0%) |
| Dec 2017 | $0.00(-100.0%) | - |
| Dec 2017 | - | $0.00(-100.0%) |
| Jun 2017 | - | $781.90 K(-21.4%) |
| Dec 2016 | $995.10 K(>+9900.0%) | - |
| Dec 2016 | - | $995.10 K(-71.4%) |
| Jun 2016 | - | $3.49 M(>+9900.0%) |
| Dec 2015 | $0.00(-100.0%) | - |
| Dec 2015 | - | $0.00(-100.0%) |
| Jun 2015 | - | $586.50 K(-51.2%) |
| Jun 2014 | - | $1.20 M(-85.3%) |
| Jun 2013 | - | $8.17 M |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $3200.00(-94.2%) | - |
| Dec 2012 | - | $3200.00(-98.2%) |
| Jun 2012 | - | $175.30 K(+215.9%) |
| Dec 2011 | $55.50 K(-94.0%) | - |
| Dec 2011 | - | $55.50 K(-91.3%) |
| Jun 2011 | - | $638.10 K(-30.9%) |
| Dec 2010 | $923.00 K(+246.0%) | - |
| Dec 2010 | - | $923.00 K(+7.4%) |
| Jun 2010 | - | $859.20 K(+222.0%) |
| Dec 2009 | $266.80 K(-73.7%) | - |
| Dec 2009 | - | $266.80 K(-77.6%) |
| Jun 2009 | - | $1.19 M(+17.6%) |
| Dec 2008 | $1.01 M(+153.9%) | - |
| Dec 2008 | - | $1.01 M(-48.9%) |
| Jun 2008 | - | $1.98 M(+397.2%) |
| Dec 2007 | $399.20 K(+21.3%) | - |
| Dec 2007 | - | $399.20 K(-81.0%) |
| Jun 2007 | - | $2.10 M(+539.0%) |
| Dec 2006 | $329.00 K(+20.3%) | - |
| Dec 2006 | - | $329.00 K(+20.3%) |
| Dec 2005 | $273.40 K(-66.9%) | - |
| Dec 2005 | - | $273.40 K(-66.9%) |
| Dec 2004 | $825.30 K(-47.5%) | - |
| Dec 2004 | - | $825.30 K(-47.5%) |
| Dec 2003 | $1.57 M(+16.3%) | - |
| Dec 2003 | - | $1.57 M |
| Dec 2002 | $1.35 M(+3116.7%) | - |
| Dec 2001 | $42.00 K(-93.0%) | - |
| Dec 2000 | $596.40 K(+197.6%) | - |
| Dec 1999 | $200.40 K(-42.3%) | - |
| Dec 1998 | $347.30 K(+424.6%) | - |
| Dec 1997 | $66.20 K(+5.2%) | - |
| Dec 1996 | $62.90 K(-97.8%) | - |
| Dec 1995 | $2.80 M | - |
FAQ
- What is Silence Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Silence Therapeutics?
- What is Silence Therapeutics annual accounts receivable year-on-year change?
- What is Silence Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Silence Therapeutics?
- What is Silence Therapeutics quarterly accounts receivable year-on-year change?
What is Silence Therapeutics annual accounts receivable?
The current annual accounts receivable of SLN is $290.40 K
What is the all time high annual accounts receivable for Silence Therapeutics?
Silence Therapeutics all-time high annual accounts receivable is $39.94 M
What is Silence Therapeutics annual accounts receivable year-on-year change?
Over the past year, SLN annual accounts receivable has changed by -$816.90 K (-73.77%)
What is Silence Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of SLN is $385.40 K
What is the all time high quarterly accounts receivable for Silence Therapeutics?
Silence Therapeutics all-time high quarterly accounts receivable is $40.53 M
What is Silence Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, SLN quarterly accounts receivable has changed by +$95.00 K (+32.71%)